Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France

Published:2018-03-15 Issue:3 Volume:13 Page:e0194329
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Maunoury Franck^ORCID,Clément Aurore,Nwankwo Chizoba,Levy-Bachelot Laurie,Abergel Armand,Di Martino Vincent,Thervet Eric,Durand-Zaleski Isabelle

Funder

MSD France

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference36 articles.

1. Hepatitis C infection associated with renal disease and chronic renal failure;FF Poordad;Semin Liver Dis,2004

2. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey;K Sauné;Nephrol Dial Transplant,2011

3. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans;MZ Molnar;Hepatology,2015

4. French Association for the Liver Study (AFEF). AFEF recommendations on the management of viral hepatitis C. 2016. http://www.afef.asso.fr/mwg-internal/de5fs23hu73ds/progress?id=3hZ3SDu1Yr.

5. Twelve weeks post treatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin;M Martinot-Peignoux;Hepatology,2010

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world economic burden of hepatitis C and impact of direct‐acting antivirals in France: A nationwide claims data analysis;Liver International;2024-02-20

2. Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review;Frontiers in Public Health;2022-05-13

3. Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China;Frontiers in Pharmacology;2021-10-15

4. Cost-Effectiveness of a Serum Biomarker Test for Risk-Stratified Liver Ultrasound Screening for Hepatocellular Carcinoma;Value in Health;2021-10

5. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population;Kidney International Reports;2021-07